Lung cancer, predictive factor and ERCC1

  • Authors

    • Souad Souilah Pulmonology Department, Bab El Oued University Hospital, Algiers, Algeria Benyoucef Benkhedda University
    2024-03-06
    https://doi.org/10.14419/378xkf63

  • Abstract

    Introduction: Excision repair cross-complementing group 1 (ERCC1) counteracts the cytotoxic effect of cisplatin through its role in DNA repair, and its expression level is a crucial factor for sensitivity to this drug. The objective of this study was to assess the impact of ERCC1 on tumor response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with a platinum-based regimen.

    Methods: Analysis of survival and tumor response based on the expression level of ERCC1 (detected by immunohistochemistry) in a cohort of NSCLC patients followed in a standard care setting.

    Results: Among the 77 cases of NSCLC included, ERCC1 expression was low in 64.9% of cases and high in 35.1% of cases. In the 52 patients treated with cisplatin, survival and tumor response were better in the low-expression group compared to the high-expression group: 14.35 months versus 9.49 months, p=0.022; Objective Response: 42.4% versus 0%, p=0.001. No significant difference was found based on protein expression level in patients treated with carboplatin.

    Conclusion: ERCC1 overexpression in patients treated with cisplatin predicts a poor tumor response and shorter survival.

  • References

    1. KA. Olaussen, A. Dunant, P. Fouret, et al., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemo-therapy, The New England journal of medicine, 355, 2006, 983-91. https://doi.org/10.1056/NEJMoa060570.
    2. M. Cobo, D. Isla, B. Massuti, et al., Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expres-sion: a phase III trial in non-small-cell lung cancer, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25, 2007, 2747-54. https://doi.org/10.1200/JCO.2006.09.7915.
    3. S. Chen, J. Zhang, R. Wang, et al., The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 ex-pression better than high/positive ERCC1 expression? A meta-analysis, Lung Cancer, 70, 2010, 63-70. https://doi.org/10.1016/j.lungcan.2010.05.010.
    4. B. Holm, A. Mellemgaard, T. Skov, et al., Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine, Journal of clinical oncology: offi-cial journal of the American Society of Clinical Oncology, 27, 2009, 4254-9. https://doi.org/10.1200/JCO.2008.18.8631.
    5. K. Azuma, Y. Komohara, T. Sasada, et al., Excision repair cross-complementation group 1 predicts progression-free and overall sur-vival in non-small cell lung cancer patients treated with platinum-based chemotherapy, Cancer science, 98, 2007, 1336-43. https://doi.org/10.1111/j.1349-7006.2007.00557.x.

  • Downloads

  • How to Cite

    Souilah, S. (2024). Lung cancer, predictive factor and ERCC1. International Journal of Medicine, 12(1), 13-16. https://doi.org/10.14419/378xkf63